LENZ Therapeutics has unveiled its “Make it VIZZable” consumer campaign, featuring award-winning actor and producer Sarah Jessica Parker as brand ambassador. The nationwide initiative highlights VIZZ (aceclidine ophthalmic solution) 1.44%, a once-daily prescription eye drop designed to restore near vision for up to 10 hours. Parker, one of the estimated 128 million Americans affected by age-related blurry near vision, shares her personal experience of regaining the ability to read her phone, do her makeup and review scripts without reaching for reading glasses. The campaign is supported by digital and social media activations across Facebook, Instagram, TikTok, YouTube and LinkedIn, as well as in-office sampling through participating eye care providers.

VIZZ’s efficacy is grounded in results from the CLARITY Phase 3 trial in which 93% of participants achieved near visual acuity of 20/40 or better within 30 minutes of dosing, with improvement lasting up to 10 hours. Unlike conventional reading glasses or multifocal lenses, VIZZ employs a predominantly pupil-selective miotic mechanism: aceclidine contracts the iris sphincter muscle to create a pinhole effect and extend depth of focus without a myopic shift or significant ciliary muscle stimulation. The preservative-free formulation is supplied in single-dose vials and demonstrated a favorable safety profile, with instillation site irritation in 20% of users and transient dim vision reported by 16%.

LENZ is executing a multi-pronged commercialization plan in the United States, targeting the 45+ demographic that loses an average of 1.5 lines of near vision every six years. VIZZ is available by prescription through a network of eye care professionals; consumers can obtain a free sample by visiting VIZZ.com to locate a local provider. International licensing partnerships are in development to address presbyopia in the estimated 1.8 billion people worldwide who experience age-related near vision decline. The campaign’s launch coincides with LENZ’s efforts to establish VIZZ as a standard alternative to over-the-counter reading glasses and to capture a share of the global presbyopia market projected to exceed $5 billion by 2030.